|
Clinical Trial of HuMax-CD4, a new drug to treat Advanced Stage T-Cell Lymphoma in the skin. Clinical Trials Information presented on Clinical Trials Search isn't intended to be a substitute for proven healthcare advice, trips or treatment using a real physician. We are not docs. Always confer with your mD on Clinical Trial of HuMax-CD4, a new drug to treat Advanced Stage T-Cell Lymphoma in the skin. conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Clinical Trial of HuMax-CD4, a new drug to treat Advanced Stage T-Cell Lymphoma in the skin. Clinical research trials and Clinical Trial of HuMax-CD4, a new drug to treat Advanced Stage T-Cell Lymphoma in the skin. medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectiveness of new drugs. The intention of the studies / projects is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector corporations to detect remedies for all forms of circumstances, like Clinical Trial of HuMax-CD4, a new drug to treat Advanced Stage T-Cell Lymphoma in the skin.. Clinical Trial of HuMax-CD4, a new drug to treat Advanced Stage T-Cell Lymphoma in the skin. Clinical Trials and other clinical trials allow for volunteers to undergo healthcare treatment options before they are available to the masses. Most times the participants receive treatment for free, and every now and again they are paid for their time. Occasionally there is a cost for a Clinical Trial of HuMax-CD4, a new drug to treat Advanced Stage T-Cell Lymphoma in the skin. clinical trial. Subjects typically recieve the finest healthcare available for their Clinical Trial of HuMax-CD4, a new drug to treat Advanced Stage T-Cell Lymphoma in the skin. condition. Hazards are a reality, nonetheless, and might include more or frequent mD trips, health risks (potentially life-endangering), and/or the treatment being ineffective. Trials are federally regulated with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Clinical Trial of HuMax-CD4, a new drug to treat Advanced Stage T-Cell Lymphoma in the skin.  Clinical Trial of HuMax-CD4, a new drug to treat Advanced Stage T-Cell Lymphoma in the skin.
Clinical Trial of HuMax-CD4, a new drug to treat Advanced Stage T-Cell Lymphoma in the skin.
For Condition: Cutaneous T-Cell Lymphoma
Status: Recruiting
Sponsor(s): Genmab ,
Synopsis: The purpose of this trial is to determine the effect of HuMax-CD4, as a treatment for advanced stage (late stage) cutaneous T-cell lymphoma (CTCL). Almost all patients who are affected by late stage CTCL have many cancerous cells which bear a receptor called CD4. HuMax-CD4 is an investigational drug directed against this receptor. There is no placebo in this trial; all patients will be treated with HuMax-CD4. The response rates, duration of responses, relief of symptoms, and safety profile of HuMax-CD4 will be evaluated during this trial.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion criteria - Medical diagnosis of CTCL, and positivity for the CD4 receptor. - Late stage CTCL. - Have received at least one prior anti-cancer therapy with inadequate effect. - WHO performance status 0,1 or 2 - Male or female, age 18 or older. - Signed informed consent. Exclusion Criteria - Certain rare types of CTCL. - Previous treatment with other anti-CD4 medications. - More than two previous treatments with systemic chemotherapy. - Certain anti-psoriasis or anti-cancer therapies within the last 4 weeks before entering this trial. - Some types of steroid treatments less than two weeks before entering the trial. - Prolonged exposure to sunlight or UV light during the trial. - Other cancer diseases, except certain skin cancers or cervix cancer. - Chronic infectious disease requiring medication. - Certain serious medical conditions, including kidney or liver disease, some psychiatric illnesses, and stomach, lung, heart, hormonal, nerve or blood diseases. - Certain laboratory values which are too high or too low. - HIV positivity. - Pregnant or breast-feeding women. - Women of childbearing age who are unable or unwilling to use an IUD or hormonal birth control during the whole trial. - If you are participating in another trial with a different new drug 4 weeks before you enter this trial.
Total Enrollment:
Location and Contact Information:
University of Texas, M.D. Anderson Cancer Center *No longer recruiting*
Houston, Texas, 77030-4009
United States
No longer recruiting
Stanford University Med Ctr., Dept of Dermatology *No longer recruiting*
Stanford, California, 94305-5152
United States
No longer recruiting
Additional Information:
Study ID Numbers: Hx-CD4-008;
Study Start Date:
Record last reviewed: October 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00071084
Other Cutaneous T-Cell Lymphoma Studies:
1. Pegfilgrastim Compared With Filgrastim To Increase Peripheral Stem Cells Before Autologous Stem Cell Transplantation in Treating Patients With Lymphoma
2. Characterizing Serum Protein Patterns in Selected Skin Diseases
3. FR901228 in Treating Patients With T-Cell Lymphoma
4. Gemcitabine, Carboplatin, and Dexamethasone With or Without Rituximab in Treating Patients With Relapsed or Primary Refractory Lymphoma
5. Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides
Related Studies:
Other Cutaneous T-Cell Lymphoma Clinical Trials
Other California Clinical Trials
Other Stanford Clinical Trials
Clinical Trial of HuMax-CD4, a new drug to treat Advanced Stage T-Cell Lymphoma in the skin.
|
|
|
|
|
|
|
|
